Details for Patent: 10,300,025

Which drugs does patent 10,300,025 protect, and when does it expire?

Patent 10,300,025 protects ADLARITY and is included in one NDA.

This patent has seventy-four patent family members in ten countries.

Summary for Patent: 10,300,025

Title:	Donepezil transdermal delivery system
Abstract:	A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.
Inventor(s):	Lee; Eun Soo (Redwood City, CA), Jain; Amit K. (Milpitas, CA), Singh; Parminder (Union City, CA)
Assignee:	Corium, Inc. (Menlo Park, CA)
Application Number:	15/660,939
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 10,300,025

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		RX	Yes	No			Y
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-002	Mar 11, 2022		RX	Yes	Yes			Y

International Family Members for US Patent 10,300,025

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017301928
Australia	2017301929
Australia	2017302305
Australia	2017302306
Australia	2017302307